gp120

YYA-021 inhibits HIV entry, with high anti-HIV activity and low cytotoxicity.

NBD-556 is a small molecule mimetic of CD4. NBD-556 recognizes the HIV-1 envelope protein gp120 and induces restructuring of gp120 analogous to CD4 binding.

Anti-Mouse CD4 Antibody (2G5.D) is an anti-mouse CD4 antibody widely used in research and experiments in the field of life sciences.

Ingenol mebutate (Ingenol 3-Angelate) is a potent activator of PKC subtypes including PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε with Kis of 0.3, 0.105, 0.162, 0.376, and 0.171 nM. Ingenol mebutate exhibits antiinflammatory and antitumor activity.

(4S,5S)-(+)-Germacrone-4,5-epoxide inhibits certain subtypes of cytochrome P450 (CYP).

Moringin is an isothiocyanate obtained from myrosinase-mediated hydrolysis of the glucosinolate precursor glucoMoringin present in Moringa oleifera seeds. Moringin has anti-inflammatory and antioxidative properties.

Physalin H is an Hh signaling inhibitor blocks GLI1-DNA-complex formation, it also strong quinone reductase induction activity with IR (Induction ratio, QR induction activity) value of 3.74±0.02. Physalin H shows immunosuppressive effects on T cells both

gp120-α4β7 binding inhibitor 11 is an anti-HIV agent. gp120-α4β7 binding inhibitor 11 interferes the binding of HIV associated glycoprotein gp12G with the integrin α4β7 (IC50=1.64nM).

gp120-IN-2 (compound 4i) is a potent inhibitor of HIV-1 gp120, demonstrating anti-HIV-1 activity with an IC50 of 7.5 μM and a CC50 of 112.93 μM. It shows dose-dependent cytotoxicity in SUP-T1 cells [1].

gp120-IN-1 (compound 4e) is a potent HIV-1 gp120 inhibitor with a CC50 of 100.90 μM and IC50 of 2.2 μM, inhibiting gp120-mediated virus entry into cells and exhibiting anti-HIV-1 activity with dose-dependent cytotoxicity in SUP-T1 cells [1].

GP120, HIV-1 MN, a peptide, is utilized in researching HIV infection [1] [2].

Anti-HIV gp120 Antibody (55-36) is a chimeric mouse IgG1 κ antibody designed to target HIV gp120. The recommended isotype control for this antibody is Mouse IgG1 kappa, Isotype Control.

HIV gp120 254-274, a conserved fragment of the envelope glycoprotein gp120 from the human immunodeficiency virus (HIV), displays immunosilent activity [1].

INCB-9471 is a CCR5 antagonist with anti-HIV activity and inhibits the interaction between HIV-1 gp120.

Peptide T acetate is an octapeptide from the V2 region of HIV-1 gp120. Peptide T is a synthetic octapeptide whose possible mechanism of action is the competitive inhibition of gp120 to the CD4 receptor as well as binding to vasointestinal peptide receptors and inhibiting cytokine action

Fostemsavir Tris (BMS-663068 Tris) is the prodrug of BMS-626529,is a oral, safe and effective inhibitor of HIV-1 attachment. It inhibits human immunodeficiency virus type 1 (HIV-1) infection by binding to gp120 and interfering with the attachment of virus to CD4+ T-cells.

DS-003 is a small molecule Gp120 inhibitor. As an analog of BMS-378806, DS003 demonstrates enhanced inhibitory activity during prolonged exposure and when used in combination with fusion inhibitors. However, prior exposure to soluble CD4+ hinders DS003's binding to the viral envelope. Studies indicate that due to its targeting of the CD4+ binding site on Gp120, DS003 is a promising candidate for pre-exposure prophylactic therapy.

BMS-818251 is a potent small-molecule inhibitor that targets HIV-1 entry, with an EC50 value of 0.019 nM. It exhibits over 10 times greater efficacy on the cross-subtype panels of the 208-HIV-1 strain compared to BMS-626529. BMS-818251 enhances potency through interactions with gp120 residues in the conserved β20-β21 hairpin.

inhibitor of human CCR5 binding to HIV-1 gp120

BMS-585248 is a highly effective HIV-1 adhesion inhibitor that targets the viral envelope protein gp120.

Fostemsavir (BMS-663068) is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection.

Globotriaosycleramides are glycosphingolipids found in mammalian cell membranes that are synthesized from lactosylceramides . They act as receptors for Shiga and Shiga-like toxins in vitro and in vivo. Globotriaosylceramides accumulate in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. Globotriaosylceramides act as natural resistance factors to HIV infection, interacting with HIV gp120 to prevent its interaction with chemokine co-receptors and subsequent fusion of HIV to host cell membranes. This product contains a mixture of hydroxy fatty acid-containing globotriaosylceramides isolated from porcine red blood cells (RBCs).

Globotriaosycleramides are glycosphingolipids found in mammalian cell membranes that are synthesized from lactosylceramides . They act as receptors for Shiga and Shiga-like toxins in vitro and in vivo. Globotriaosylceramides accumulate in endothelial cells, pericytes, vascular smooth muscle cells, renal epithelial cells, dorsal ganglia neuronal cells, and myocardial cells in patients with Fabry disease, a lysosomal storage disorder characterized by a deficiency in the enzyme α-galactosidase A. Globotriaosylceramides act as natural resistance factors to HIV infection, interacting with HIV gp120 to prevent its interaction with chemokine co-receptors and subsequent fusion of HIV to host cell membranes. This product contains a mixture of hydroxy and non-hydroxy fatty acid-containing globotriaosylceramides isolated from porcine red blood cells (RBCs).